|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Bruton_tyrosine_kinase_inhibitor
|
|
gptkbp:activities
|
gptkb:Bruton_tyrosine_kinase_inhibitor
|
|
gptkbp:appointed_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:2013
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Imbruvica
|
|
gptkbp:clinical_trial
|
combination therapy
Phase 3
monotherapy
|
|
gptkbp:contraindication
|
active bleeding disorders
severe hepatic impairment
|
|
gptkbp:discovered_by
|
gptkb:Pharmacyclics
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ibrutinib
|
|
gptkbp:indication
|
first-line treatment for CLL
relapsed or refractory CLL
treatment of MCL
treatment of WM
|
|
gptkbp:ingredients
|
C19 H20 N6 O2 S
|
|
gptkbp:interacts_with
|
gptkb:Bruton_tyrosine_kinase
anticoagulants
CY P3 A4 inducers
CY P3 A4 inhibitors
|
|
gptkbp:invention
|
2027
|
|
gptkbp:is_atype_of
|
L01 X X32
|
|
gptkbp:is_available_on
|
brand name drug
|
|
gptkbp:is_used_for
|
gptkb:Waldenström's_macroglobulinemia
gptkb:healthcare_organization
mantle cell lymphoma
|
|
gptkbp:manager
|
oral
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:United_States
gptkb:Abb_Vie
gptkb:Native_American_tribe
|
|
gptkbp:pharmacokinetics
|
bioavailability 100%
half-life 4-5 hours
inhibits B-cell receptor signaling
|
|
gptkbp:research_areas
|
oncology
pharmacology
immunology
hematologic malignancies
|
|
gptkbp:side_effect
|
fatigue
nausea
hypertension
diarrhea
skin rash
thrombocytopenia
cardiac arrhythmias
increased risk of infection
pneumonitis
liver function test abnormalities
|
|
gptkbp:treatment
|
targeted therapy
|
|
gptkbp:type_of
|
936563-96-1
|